A Study of LY2801653 in Advanced Cancer

I3O-MC-JSBA -

The purpose of this study is to determine a recommended phase 2 dose of LY2801653 that may be safely given to participants with gastric cancer when taken with ramucirumab.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Advanced Cancer
What the trial is testing?
Ramucirumab, Cetuximab, Merestinib, Gemcitabine, Cisplatin
Could I receive a Placebo?
No
Enrollment Goal
190
Trial Dates
Sep 9, 2009 - Sep 11, 2017
How long will I be in the trial?
Your participation may continue for as long as you and your study doctor feel that you are benefiting from the study treatment.
Trial Phase
I

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.